Biogen, Inc. (BIIB)
217.15
+1.72
(+0.80%)
USD |
NASDAQ |
Sep 11, 16:00
216.61
-0.54
(-0.25%)
After-Hours: 06:17
Biogen Enterprise Value : 39.14B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 39.14B |
| September 10, 2026 | 38.89B |
| September 09, 2026 | 38.19B |
| September 08, 2026 | 38.46B |
| September 04, 2026 | 39.69B |
| September 03, 2026 | 40.23B |
| September 02, 2026 | 39.96B |
| September 01, 2026 | 38.98B |
| August 31, 2026 | 39.07B |
| August 28, 2026 | 39.34B |
| August 27, 2026 | 39.79B |
| August 26, 2026 | 39.72B |
| August 25, 2026 | 39.68B |
| August 24, 2026 | 39.29B |
| August 21, 2026 | 39.09B |
| August 20, 2026 | 38.73B |
| August 19, 2026 | 39.79B |
| August 18, 2026 | 38.46B |
| August 17, 2026 | 37.96B |
| August 14, 2026 | 38.06B |
| August 13, 2026 | 38.18B |
| August 12, 2026 | 37.92B |
| August 11, 2026 | 37.18B |
| August 10, 2026 | 37.66B |
| August 07, 2026 | 37.78B |
| Date | Value |
|---|---|
| August 06, 2026 | 37.54B |
| August 05, 2026 | 37.59B |
| August 04, 2026 | 37.86B |
| August 03, 2026 | 36.88B |
| July 31, 2026 | 37.05B |
| July 30, 2026 | 37.78B |
| July 29, 2026 | 37.97B |
| July 28, 2026 | 37.44B |
| July 27, 2026 | 36.63B |
| July 24, 2026 | 36.93B |
| July 23, 2026 | 36.70B |
| July 22, 2026 | 36.28B |
| July 21, 2026 | 37.08B |
| July 20, 2026 | 36.60B |
| July 17, 2026 | 37.49B |
| July 16, 2026 | 37.93B |
| July 15, 2026 | 36.20B |
| July 14, 2026 | 35.42B |
| July 13, 2026 | 37.94B |
| July 10, 2026 | 36.48B |
| July 09, 2026 | 36.45B |
| July 08, 2026 | 36.66B |
| July 07, 2026 | 37.45B |
| July 06, 2026 | 37.86B |
| July 02, 2026 | 38.99B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ionis Pharmaceuticals, Inc. | 9.114B |
| AbbVie, Inc. | 518.65B |
| Regeneron Pharmaceuticals, Inc. | 75.51B |
| Gilead Sciences, Inc. | 199.64B |
| Vertex Pharmaceuticals, Inc. | 124.70B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 97.50M |
| Revenue (Quarterly) | 2.622B |
| Total Expenses (Quarterly) | 2.525B |
| EPS Diluted (Quarterly) | 0.6557 |
| Gross Profit Margin (Quarterly) | 61.37% |
| Profit Margin (Quarterly) | 3.72% |
| Earnings Yield | 2.60% |
| Operating Earnings Yield | 5.87% |
| Normalized Earnings Yield | 4.207 |